![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Multiple Myeloma
1. Circulating Tumor Cells- Non-Invasive Biomarker for Staging Myeloma | Luca Bertamini, MD | #EHA2025 Video
2. First-In-Human Study for Novel Trispecific Antibody | Rakesh Popat, BSc, MBBS, MRCP, PhD | #EHA2025 Video
3. Arlo‑Cel, a GPRC5D CAR‑T, Breakthrough for Relapsed/Refractory Myeloma | Krina Patel, MD | #EHA2025 Video
4. Promising Result from a Novel Mezigdomide Combination Trial | Fredrik Schjesvold, MD, PhD | #EHA2025 Video
5. Belantamab Mafodotin in the Real World: Promising Myeloma Data | Fredrik Schjesvold, MD, PhD | #EHA2025 Video
6. MagnetisMM-6: Elranatamab+Dara+Len in ND Transplant-Ineligible MM | Meletios Dimopoulos, MD | #EHA2025 Video
7. Updated DREAMM-8 Data: Belantamab-Pomalidomide-Dex in Myeloma | Meletios Dimopoulos, MD | #EHA2025 Video
8. Can AI Predict Cytokine Release Syndrome Early? New Insights from EHA2025 | Yi Lin, MD, PhD | #EHA 2025 Video
9. Slowing CAR-T Cell Expansion with Steroids 2 Prevent Delayed Neurotoxicity | Yi Lin, MD | #EHA2025 Video
10. CONCEPT Trial | Isa-KRd : New Hope for High-Risk Myeloma Patients | Lisa Leypoldt, MD | #EHA2025 Video
11. Etentamig: A New BCMA Bispecific Antibody Showing Safety & Promise | Muhamed Baljevic, MD | #EHA2025 Video
12. IRAKLIA Trial: On-Body Subcutaneous Isatuximab Delivery in Myeloma | Muhamed Baljevic, MD | #EHA2025 Video
13. New Hope for MRD Recurrence? Daratumumab Proof-of-Concept Study | Krzysztof Jamroziak, MD | #EHA2025 Video
14. New Insights into High-Risk Amyloidosis Staging | Jahanzaib Khwaja, MD, FRCPath | #EHA2025 Video
15. Diagnosing Myeloma? Don’t Skip This Critical Amyloidosis Test! Jahanzaib Khwaja, MD, FRCPath Video
16. Personalizing Treatment with On-body Delivery of Isatuximab | Claudio Cerchione, MD | #EHA2025 Video
17. Unmet Medical Needs of Patients Who are Lenalidomide Refractory | Claudio Cerchione, MD | #EHA2025 Video
18. Belantamab Mafodotin Updates & How to Manage Eye Side Effects | Evangelos Terpos, MD, PhD | #EHA2025 Video
19. The Importance of Joining Clinical Trials | Sunil Gupta, FCRPath, MRCP, DNB | EHA 2025 #myeloma Video
20. Revolutionizing Myeloma Care: AI Matches Patients to Trials | Jorge Hurtado Martinez, MD | EHA 2025 Video
21. HDP‑101: Promising Anti‑BCMA ADC with Novel Payload for Myeloma | Shambavi Richard, MD | EHA 2025 Video
22. MIDAS Trial Updates | Isa-KRd in NDMM | Paul Richardson, MD | EHA 2025 #myeloma Video
23. All-Oral Myeloma Combo: Mezigdomide + Tazemetostat or Trametinib | Paul Richardson, MD | EHA 2025 Video
24. Multiomics Reveal MRD Kinetics & Early Immunotherapy Response in Myeloma | Bruno Paiva, PhD | #EHA2025 Video
25. Could Clonotypic B Cells Be the Key to Myeloma & AL Amyloidosis Origins? | Bruno Paiva, PhD | EHA25 Video
26. ADVANCE Trial | Dara‑KRd in NDMM yields ~ 60% MRD‑Negativity| Ola Landgren, MD, PhD- #EHA25 #myeloma Video
27. High‑Risk Myeloma Redefined by IMWG | Craig Cole, MD | EHA 2025 Insights Video
28. Real-World Evidence for Teclistamab in Myeloma | Dr. Rakesh Popat Shares #EHA2025 Insights Video
29. Socioeconomic Inequalities & Quality of Life in Myeloma | Francesco Sparano, MSc | #EHA2025 Video
99. IRAKLIA- On-Body Isatuximab Matches IV Delivery = More Convenient Care| Claudio Cerchione,MD | EHA25 Video
Arlo‑Cel, a GPRC5D CAR‑T, Breakthrough for Relapsed/Refractory Myeloma | Krina Patel, MD | #EHA2025
2 months ago
Lesson Description
In this EHA 2025 highlight, Dr. Krina Patel shares the latest data on Arlo-Cel, a next-generation CAR-T cell therapy targeting GPRC5D in relapsed/refractory multiple myeloma. Discover how this investigational therapy is performing in early trials, what makes it different from BCMA-targeted CAR-Ts, and why it could offer renewed hope for patients with limited options.